Sells extended-release ADHD medicines, along with a depression medicine and an allergy treatment, to wholesalers and pharmacies.
10-K for FY2026, filed Sep 22, 2026Our business from continuing operations is focused on the commercial launch and growth of EXXUA and on our current prescription…View ↗
Our business consists of EXXUA, which we launched in fiscal 2026, our ADHD Portfolio and our Pediatric Portfolio. Our prescription products…View ↗
Our ADHD products are extended-release stimulant medications formulated in patient-friendly, orally disintegrating tablets (“ODT”) that…View ↗
Our prescription Pediatric Portfolio primarily includes Karbinal ER, an extended-release carbinoxamine (a first-generation antihistamine)…View ↗
The company sells prescription medicines through wholesalers and distributors and also directly to pharmacy customers.
10-K for FY2026, filed Sep 22, 2026We operate through one business segment consisting of various prescription pharmaceutical products sold through third parties. We generate…View ↗
Not on paper. It lost $14.3M in FY2026, but brought in more cash than it spent: $3.3M of free cash flow.
Consumer Health exit
The older report described prescription drugs and consumer health products sold directly to consumers. The latest report describes a prescription-focused business after the Consumer Health wind-down and divestiture.
10-K for FY2023, filed Oct 12, 2023 10-K for FY2026, filed Sep 22, 2026We operate through two business segments (i) the Rx Segment, consisting of various prescription pharmaceutical products sold through third…View ↗
Our Consumer Health Segment is dedicated to commercializing safe and effective “over-the-counter” (“OTC”) medicines, personal care…View ↗
The Consumer Health Segment currently sells directly to consumers primarily in the United States through e-commerce platforms, including…View ↗
Added depression treatment
The latest report adds EXXUA, a depression medicine, to the commercial portfolio and makes it the centerpiece of sales efforts; the older report described ADHD and pediatric prescription portfolios.
10-K for FY2023, filed Oct 12, 2023 10-K for FY2026, filed Sep 22, 2026Our Rx Segment consists of our ADHD Portfolio and our Pediatric Portfolio. Our prescription products are sold solely in the United States…View ↗
We acquired our ADHD Portfolio in March 2021 with the acquisition of Neos Therapeutics. These commercial ADHD products are extended-release…View ↗
Our prescription Pediatric Portfolio includes Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat…View ↗
Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing…View ↗
We operate through one business segment consisting of various prescription pharmaceutical products sold through third parties. We generate…View ↗
EXXUA is an extended-release medication that is FDA-approved for the treatment of MDD with what we believe to be a novel first-in-class…View ↗
Competes with Granules
10-K for FY2026, filed Sep 22, 2026On October 31, 2024, we received a Paragraph IV Certification Notice Letter (the “Notice Letter”) from Granules Pharmaceuticals, Inc.…View ↗
Loading...